<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00193921</url>
  </required_header>
  <id_info>
    <org_study_id>TROG 03.07</org_study_id>
    <secondary_id>PMCC Protocol No. 03/85</secondary_id>
    <nct_id>NCT00193921</nct_id>
  </id_info>
  <brief_title>Chemoradiotherapy in Patients With Localised Lung Cancer</brief_title>
  <official_title>A Randomised Phase II Study of Two Regimens of Palliative Chemoradiation Therapy in the Management of Locally Advanced Non Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trans Tasman Radiation Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Council Queensland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Victorian Cancer Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Trans Tasman Radiation Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study compares 2 different methods of combined chemotherapy and radiotherapy for the&#xD;
      treatment of localised lung cancer in patients not suitable for surgery.&#xD;
&#xD;
      Hypothesis(es) to be tested:&#xD;
&#xD;
        1. Vinorelbine + cisplatin + high-dose palliative radiotherapy is superior to gemcitabine +&#xD;
           high dose palliative radiotherapy in terms of efficacy in a multi-institutional setting&#xD;
&#xD;
        2. Vinorelbine + cisplatin + high-dose palliative radiotherapy is superior to gemcitabine +&#xD;
           high dose palliative radiotherapy in terms of feasibility in a multi-institutional&#xD;
           setting&#xD;
&#xD;
        3. Vinorelbine + cisplatin + high-dose palliative radiotherapy has a favourable toxicity&#xD;
           profile relative to gemcitabine + high-dose palliative radiotherapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A third of patients with non-small cell lung cancer (NSCLC) present with Stage IIIA or IIIB&#xD;
      disease, which is not amenable to curative resection. Single modality local therapy, either&#xD;
      surgery or radiation, only cures a fraction of such patients.&#xD;
&#xD;
      Radical radiation is not feasible for all patients with unresectable Stage IIIA or IIIB&#xD;
      non-small cell lung cancer, based upon the extent of the loco-regional disease or the medical&#xD;
      state of the patient. Patients of good performance status receiving protracted high-dose&#xD;
      palliative radiotherapy do obtain a survival benefit from this therapy. Studies have shown a&#xD;
      survival advantage by adding chemotherapy to radical radiation therapy: but studies in the&#xD;
      high-dose palliative radiotherapy setting are lacking. Two regimens of concurrent&#xD;
      chemotherapy with high-dose palliative radiotherapy have been developed locally, with&#xD;
      established MTDs. These 2 regimens do warrant a comparative assessment in a phase II trial,&#xD;
      prior to a phase III trial against high dose palliative radiation alone (36Gy/12#/5).&#xD;
&#xD;
      This is a randomised phase II trial comprising of 2 arms for randomization as follows:&#xD;
&#xD;
      Arm A:External beam radiation, 40 Gy/20#/5 per week, Plus concurrent Vinorelbine, IV,&#xD;
      25mg/m2, days 1, 8, 22 and + Cisplatin 20mg/m2, IV, weekly&#xD;
&#xD;
      Arm B:External beam radiation, 30 Gy/15#/5 per week, Plus concurrentGemcitabine, 200mg (flat&#xD;
      dose) IV days 1, 8, 15&#xD;
&#xD;
      An equal number of patients will be randomised to each arm. The randomisation will be carried&#xD;
      out by the Princess Alexandra Trial Centre.&#xD;
&#xD;
      Patients will be assessed at baseline, weekly during treatment, and then at 3 weeks, 6 weeks&#xD;
      and 12 weeks post treatment then 3 monthly thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (RECIST criteria)</measure>
    <time_frame>Final analysis will occur when all have a minimum 1 year follow-up after randomisation. Approx 3 years after start of trial.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptomatic response rate</measure>
    <time_frame>Final analysis will occur when all have a minimum 1 year follow-up after randomisation. Approx 3 years after start of trial.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The feasibility (i.e. % of patients who cannot complete the planned RT dose or who require a break for toxicity) and problems encountered with protocol compliance in the setting of a multi-institutional TROG study.</measure>
    <time_frame>Final analysis will occur when all have a minimum 1 year follow-up after randomisation. Approx 3 years after start of trial.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity of both treatments</measure>
    <time_frame>Final analysis will occur when all have a minimum 1 year follow-up after randomisation. Approx 3 years after start of trial.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Final analysis will occur when all have a minimum 1 year follow-up after randomisation. Approx 3 years after start of trial.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOL as assessed by FACT-L version 4.</measure>
    <time_frame>Final analysis will occur when all have a minimum 1 year follow-up after randomisation. Approx 3 years after start of trial.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Non Small Cell Lung Carcinoma</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vinorelbine + cisplatin + high-dose palliative radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gemcitabine + high-dose palliative radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
    <description>IV, 25mg/m2, days 1, 8, 22</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Navelbine, Vinorelbine Ebewe</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>High dose Radiotherapy</intervention_name>
    <description>External beam radiation, 40 Gy/20#/5 per week</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>200mg (flat dose) IV days 1, 8, 15</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Gemzar, Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>20mg/m2, IV, weekly</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Cisplatin Ebewe, Cisplatin Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>High Dose Radiotherapy</intervention_name>
    <description>External beam radiation, 30 Gy/15#/5 per week</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Radiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically proven non-small cell lung cancer.&#xD;
&#xD;
          -  Planned high dose palliative radiation therapy for locoregional control. Examples&#xD;
             include patients with:&#xD;
&#xD;
               1. Stage I - IIIB disease with&#xD;
&#xD;
                    -  disease technically unsuitable for radical therapy, or Â· weight loss in&#xD;
                       excess of 10%, or&#xD;
&#xD;
                    -  concurrent medical illness&#xD;
&#xD;
               2. Patients found to have a locally advanced thoracic disease suitable for radical&#xD;
                  therapy but on work up are found to have a FDG-PET only solitary metastasis.&#xD;
&#xD;
          -  All potential patients, prior to registration, must be reviewed at a multidisciplinary&#xD;
             lung oncology meeting attended by medical oncologists, radiation oncologists and&#xD;
             radiologists.&#xD;
&#xD;
          -  No prior radiotherapy or chemotherapy for non-small cell lung cancer.&#xD;
&#xD;
          -  ECOG performance status 0, 1.&#xD;
&#xD;
          -  Adequate hepatic, bone marrow and renal function.&#xD;
&#xD;
          -  If patient is female of child bearing potential, she must not be pregnant or&#xD;
             lactating. Males and females of reproductive potential must practise adequate&#xD;
             contraception.&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient unable to receive all therapy as an outpatient.&#xD;
&#xD;
          -  Significant medical conditions which in the opinion of the investigator would&#xD;
             compromise the planned delivery of the chemotherapy and radiotherapy or which may be&#xD;
             potentially exacerbated by these modalities.&#xD;
&#xD;
          -  History of any other cancer (except non-melanoma skin cancer or carcinoma in situ of&#xD;
             the cervix) unless in complete remission and off all therapy for that cancer for at&#xD;
             least 5 years.&#xD;
&#xD;
          -  Receiving treatment with another investigational agent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Michael</last_name>
    <role>Study Chair</role>
    <affiliation>Peter MacCallum Cancer Centre, Australia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bryan Burmeister</last_name>
    <role>Study Chair</role>
    <affiliation>Princess Alexandra Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Calvary Mater Newcastle</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Queensland Oncology Service</name>
      <address>
        <city>Townsville</city>
        <state>Queensland</state>
        <zip>4810</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The John Flynn Hospital</name>
      <address>
        <city>Tugun</city>
        <state>Queensland</state>
        <zip>4224</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frankston Hospital</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>8006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Border Medical Oncology</name>
      <address>
        <city>Wondonga</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>http://www.trog.com.au</url>
    <description>Click here for more information about this study on the TROG official website</description>
  </link>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>July 31, 2014</last_update_submitted>
  <last_update_submitted_qc>July 31, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chemoradiotherapy</keyword>
  <keyword>High dose</keyword>
  <keyword>palliative radiotherapy</keyword>
  <keyword>Quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

